Lexicon Pharmaceuticals to Participate in the Jefferies 2022 Healthcare Conference
June 01, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, June 01, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Lonnel Coats, Lexicon’s chief executive officer, will present at the...
Lexicon Resubmits New Drug Application for Sotagliflozin for the Treatment of Heart Failure
May 31, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 31, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it has resubmitted a New Drug Application (NDA) to the U.S. Food and Drug...
Lexicon Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Clinical Update
May 05, 2022 06:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, May 05, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended March 31, 2022 and provided an update...
Lexicon Pharmaceuticals to Host First Quarter 2022 Financial Results Conference Call and Webcast on May 5, 2022
April 29, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 29, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), will release its first quarter 2022 financial results on Thursday, May 5, 2022 before the...
Lexicon Pharmaceuticals to Participate in the 21st Annual Needham Virtual Healthcare Conference
April 07, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 07, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Jeffrey L. Wade, Lexicon’s president and chief financial officer, will...
Lexicon Welcomes New Guidelines for the Management of Heart Failure
April 04, 2022 08:00 ET
|
Lexicon Pharmaceuticals, Inc.
Guidelines issued jointly by the American Heart Association, American College of Cardiology and Heart Failure Society of America New guidelines recommend the use of SGLT inhibitors for the prevention...
Sotagliflozin Improved Outcomes in Patients With and Without Prior Cardiovascular Disease in New Analysis Presented at the American College of Cardiology's 71st Annual Scientific Session (ACC.22)
April 02, 2022 12:15 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, April 02, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced results of a new analysis of data from the SCORED Phase 3 clinical trial of...
New Analysis of Cardiovascular Endpoints in the SCORED Trial to Be Presented at the American College of Cardiology’s 71st Annual Scientific Session (ACC.22)
March 21, 2022 08:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 21, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that an analysis of sotagliflozin data from the SCORED Phase 3 clinical trial...
Lexicon Enters Into Loan Facility With Oxford Finance for Up to $150 Million to Support Planned Commercialization of Sotagliflozin
March 17, 2022 16:14 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, March 17, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced it entered into a loan facility with Oxford Finance LLC that provides up to $150...
Lexicon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Clinical Update
February 28, 2022 06:01 ET
|
Lexicon Pharmaceuticals, Inc.
THE WOODLANDS, Texas, Feb. 28, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today reported financial results for the three months and full-year ended December 31, 2021 and...